Profile
Company facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE268B01013
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.9
About
About Krebs Biochemicals & Industries Limited
Krebs Biochemicals & Industries Limited engages in the manufacture of active pharmaceutical ingredients in India. It offers androstenedione for steroid intermediate indications, as well as lovastatin and simvastatin for anti-cholesterol applications. The company also develops amlodipine and telmisartan for anti-hypertension; cetirizine for antihistamine; orlistat for anti-obesity; serratiopeptidase for anti-inflammatory; and phenylephrine for cold and cough. In addition, it provides contract manufacturing services for large pharmaceutical and multinational companies. The company was incorporated in 1991 and is based in Visakhapatnam, India.
Visit company website
5 years, 6 months ago
Krebs Biochemicals & Industries Limited is currently in a long term uptrend where the price is trading 4.5% above its 200 day moving average.
From a valuation standpoint, the stock is 8.6% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 5.2.
Krebs Biochemicals & Industries Limited's total revenue sank by 14.4% to $65M since the same quarter in the previous year.
Its net income has dropped by 13.4% to $-83M since the same quarter in the previous year.
Finally, its free cash flow grew by 0.5% to $-120M since the same quarter in the previous year.
Based on the above factors, Krebs Biochemicals & Industries Limited gets an overall score of 2/5.